Coronary Artery Disease Clinical Trial
Official title:
Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease.
In human purified platelets, only thrombin, and not the other platelet agonists, leads to a
transient activation of the protein kinase activated by AMP (AMPK) and to phosphorylation of
its "bona fide" substrate, ACC on its Ser79. ACC phosphorylation (P-ACC) can be an
interesting marker of thrombin action on platelets. Indeed platelet and coagulation
interplay, though undoubtedly present in atherosclerosis and atherothrombosis, remains
difficult to assess. Our group showed that atherosclerotic mice (SRBI/Apolipoprotein E
knock-out) had higher platelet P-ACC compared to corresponding control mice (C57BL6). In
agreement with these data, preliminary results showed increased platelet P-ACC in a small
cohort of patients admitted for coronary angiogram, with demonstrated coronary artery
disease (CAD).
In the light of our preliminary results, we sought to analyze platelet P-ACC in a large
prospective clinical trial (ACCTHEROMA) in patients admitted for coronary angiogram. The aim
of the study is to compare platelet P-ACC in platelets of patients with CAD and more
particularly in unstable CAD patients to non-CAD patients. This study could potentially
identify patients at high risk of future ischemic cardiovascular events, because of a higher
level of thrombin generation.
Consecutive patients with planned coronary angiogram at the Cliniques Universitaires Saint
Luc, Brussels, whatever the indication, will be included between March 2015 and February
2016. Informed consent will be obtained before angiogram.
A. Blood Sampling Routine veinous blood sample will be done under fasting condition in the
cardiology ward before the angiogram (standard of care for patients undergoing coronary
angiogram).
In order to avoid additional puncture for blood sampling and to limit platelet activation,
blood samples are withdrawn after sheath insertion at the Cath lab before any drug
administration. The following measurements will be done:
- Routine coagulation tests including international rationalize ratio, activated
cephaline time, thrombin time, prothrombin time, Fibrinogen, DDimers.
- Platelet reactivity testing by the Multiple Electrode Aggregometer (Multiplate
Analysis)
- Platelet isolation and lysates will be stocked frozen for phospho-protein analysis by
immunoblotting and electrochemiluminescence (ECLIA)
- Aliquots of poor platelet plasma stocked frozen for inflammation (HsCRP), thrombin
generation tests (thrombin-antithrombin complex, prothrombin fragment F1.2, endogenous
thrombin generation potential-ETP), platelet activation markers (platelet factor 4,
soluble CD40ligand, soluble P-selectin) and circulating micro-RNA extraction.
- Platelet isolation and further purification for platelet specific micro-RNA extraction.
B. Atherosclerosis evaluation All patients underwent coronary angiogram. Significant
coronary artery lesion is defined as a luminal stenosis above 50%. Syntax score will be
calculated for all patients.
Global atherosclerotic plaque burden on coronary and extracoronary arteries will be
evaluated by measuring calcium score on thoraco-abdominal scanner with prospective
ECG-gating in a randomly selected subgroup of patients. Coronary artery calcification (CAC)
is expressed as Agatston score using calcium scoring software (Philips Healthcare) with a
threshold of 130 Hounsfield units. The degree of atherosclerotic burden on coronary arteries
is classified as mild (Agatston score <100), moderate (Agatston score 100-400) or severe
(Agatston score >400). Aortic calcification (AoC score) was measured from aortic arch to
iliac arteries in all patients.
C. Data collection Baseline characteristics of patients will be collected from the medical
database of the Cliniques Universitaires Saint Luc. All coronary angiogram will be reviewed
by 2 different investigators and syntax score will be calculated with the online syntax
score calculator. CAC Agatston and AoC score will also be assessed by 2 different
investigators.
D.Patients Classification for platelet P-ACC analysis Platelet ACC phosphorylation (P-ACC)
analysis will be done by immunoblotting with a specific antibody probing for phosphorylated
(Ser 79) ACC. Purified washed platelets stimulated with 0.5 units/ml thrombin will be used
as positive internal controls.
Patients will first be classified in non-CAD and CAD groups based on the results of coronary
angiogram and CAC Agatston score: Non-CAD (absence of lesion on angiogram and/or CAC
Agatston score<100) and CAD (presence of at least 1 lesion on angiogram and/or CAC Agatston
score>100).
In a second analysis, based on clinical presentation, the CAD group will further be divided
into Stable CAD or Unstable CAD [acute coronary syndrome (ACS)]. Platelet P-ACC will be
compared in both subgroups. This detailed classification will outline high-risk patients
with ongoing acute coronary syndrome.
E. Sample size and statistical analysis. Based on our preliminary data, we determined that
enrolment of 102 patients would provide a power of 80% at a significance level of 5% to
detect a difference of 0.15 (A.U.) in the phosphorylation of ACC in atherosclerotic
patients, compared to non CAD patients.
Continuous variables will be expressed as mean +/- one standard deviation, categoric
variables as counts and percentages. Patients will separated in four groups depending on the
level of P-ACC (quartiles). Clinical presentation, thrombin generation markers and calcium
scoring will be compared in all these groups, based on ANOVA analysis. Variables will be
submitted to logistic regression test in order to identify independent predictors of high
ACC phosphorylation state. The role of high platelets P-ACC in assessing the risk of the
patients will be then studied.
F.Follow-up A follow-up period of 3 years is planned. Events recorded during the follow-up
period will be obtained from the medical database and a phone call will be done in case of
missing data.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |